Page last updated: 2024-11-13
stampidine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
stampidine: an anti-HIV agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 23277358 |
SCHEMBL ID | 14596599 |
MeSH ID | M0447336 |
Synonyms (4)
Synonym |
---|
stampidine |
SCHEMBL14596599 |
DTXSID00875230 |
d4t,p-bromophenyl-methoxyalanyl phosphate |
Research Excerpts
Effects
Excerpt | Reference | Relevance |
---|---|---|
"Stampidine has a favorable pharmacokinetic profile in mice, rats, dogs and cats with 25 or 50 mg/kg tolerable dose levels yielding micromolar plasma concentrations that are 1000-fold higher than its in vitro IC(50) value against HIV." | ( Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS. Cahn, P; D'Cruz, O; Qazi, S; Uckun, FM, 2012) | 2.54 |
Actions
Excerpt | Reference | Relevance |
---|---|---|
"Stampidine did not cause mucosal inflammation." | ( Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. D'Cruz, OJ; Samuel, P; Uckun, FM; Waurzyniak, B, 2003) | 1.27 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" No STAMP-related toxic lesions were found in any of the organs from STAMP-treated cats or dogs." | ( In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Erbeck, D; Tibbles, H; Uckun, FM; Venkatachalam, TK; Waurzyniak, B, 2006) | 0.57 |
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" In accordance with its favorable pharmacokinetic profile and in vitro potency, STAMP exhibited dose-dependent and potent in vivo anti-HIV activity in Hu-PBL-SCID mice against a genotypically and phenotypically nucleoside analog reverse transcriptase inhibitor (NRTI)-resistant clinical HIV type 1 (HIV-1) isolate (BR/92/019; D67N, L214F, T215D, K219Q) at nontoxic dose levels." | ( In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice. Chen, CL; Lisowski, E; Pendergrass, S; Qazi, S; Uckun, FM; Venkatachalam, TK; Waurzyniak, B, 2002) | 0.52 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"A powerful statistical method was designed using JMP software to detect factors contributing to differences in the dissolution process of an antiviral drug delivered in an oral dosage form." | ( Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. Qazi, S; Samuel, NK; Uckun, FM; Venkatachalam, TK, 2003) | 0.32 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (31)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 29 (93.55) | 29.6817 |
2010's | 1 (3.23) | 24.3611 |
2020's | 1 (3.23) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.07) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (16.13%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 26 (83.87%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |